By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on Yang's thesis, citing high customer acquisition costs, thin margins, and significant risks in telecom and pharma sectors dominated by oligopolies. The 'cost-plus' model's sustainability and ability to scale are major concerns.
Risk: High customer acquisition costs and thin margins, exacerbated by supplier risk and potential regulatory pushback.
Opportunity: Potential regulatory arbitrage and political support if startups capture significant market share, as argued by Gemini.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Loading the player...
Entrepreneur and former presidential candidate Andrew Yang has a theory about where the next wave of startup opportunity lies, and it starts with a question most founders aren’t asking: what if the business model was giving money back instead of extracting it?
Yang was inspired by Mark Cuban. Not by his wealth, or his celebrity, but by Cost Plus Drugs — Cuban’s startup that sells pharmaceuticals at cost. Yang made a list.
“Housing, education, food, fuel, transportation, media, and wireless,” Yang told TechCrunch on a recent episode of Equity. “The things we all spend money on.”
He picked wireless and last September launched Nobile Mobile, a new mobile virtual network operator that provides cell service for a fraction of what traditional carriers charge and gives customers money back if they use less data.
As AI threatens to compress wages and displace workers, Yang sees a business opportunity in bringing down the cost of living. Cost Plus Drugs, Noble Mobile, dumb phone makers like Light Phone, and even online grocery store Misfits Markets are early examples of an emerging business category where the startup’s value proposition is the margin it gives back to the customer.
“AI is going to suck up a lot of the value and the jobs, and then Americans are going to look up and say, ‘How do I meet basic needs?’” Yang said. He believes meeting people’s needs “less expensively” is “a very rich vein of opportunity.”
That instinct didn’t emerge from nowhere. Yang first launched himself into the public eye during his 2020 presidential campaign, during which he advocated for Universal Basic Income as a means of combating AI-related workforce displacement and wealth concentration. The campaign didn’t succeed but the thesis has only grown more relevant.
Yang is still an advocate for UBI, arguing that the value generated by AI companies needs to be redistributed into the hands of the average American. But whether the government will be the vehicle for that redistribution, or whether it will just use any collected wealth to “plug a hole and do something not terribly productive,” Yang is less certain.
“There is room for a direct connection between the money and the people,” he said.
That’s where the market comes in. Where policy fails, Yang argues, market incentives can step in. Noble Mobile is his attempt to prove the point. Since its launch last September, the company has grown to “thousands and thousands” of customers and is bringing in “millions in revenue.”
“We’re unit profitable per customer, but we just share the profits with our subscribers with the idea that it’ll make you happy, you’ll stay around, and maybe you’ll tell your friends and family,” Yang said.
Four leading AI models discuss this article
"Noble Mobile's profit-sharing MVNO model lacks durable differentiation and will struggle to achieve meaningful scale against entrenched carriers."
Yang positions Noble Mobile and similar cost-plus models as a scalable response to AI-driven wage compression, yet the piece underplays execution risks in telecom. MVNOs historically face 20-30% annual churn and CAC exceeding $100 per user; sharing already-thin margins further compresses returns. Without proprietary spectrum or exclusive deals, differentiation rests on marketing alone. The UBI-to-startup pivot also ignores that policy-driven redistribution has repeatedly outpaced private margin givebacks in scale. Early 'thousands of customers' and 'millions in revenue' remain too small to validate the broader thesis.
Existing discount carriers like Mint have shown that aggressive pricing plus referrals can reach millions of users profitably once brand awareness crosses a threshold, suggesting Noble could follow the same path if data-sharing incentives drive organic growth faster than expected.
"Even if the concept works in pockets, near-term profitability hinges on razor-thin margins and outsized volumes, leaving the thesis highly vulnerable to price wars, regulatory shifts, and slower-than-expected adoption."
Yang’s thesis centers on startups that return profits to customers to lower cost of living (e.g., MVNOs like Noble Mobile, cost-plus drugs, misfits markets). The strongest risk is sustainability: if you’re constantly returning profits, unit economics can deteriorate unless CAC is negligible and volumes explode. Wireless MVNOs already run thin margins; customer acquisition costs and churn risk undermine profitability. In drugs, pricing at cost may invite regulatory scrutiny or political pushback and supply constraints. The article glosses over scale, cash burn, regulatory risk, and how durable the ‘money back’ proposition is once incumbents respond and pricing pressure intensifies.
The strongest counter is that the model may be a flashy marketing narrative rather than a durable business moat; as scale proceeds, margins compress, CAC rises, and regulators or competitors erode the arbitrage, making the thesis fragile.
"Margin-sharing startups are likely to remain lifestyle businesses or acquisition targets rather than true market-shifting disruptors because they lack the scale to challenge the structural cost advantages of established incumbents."
Yang’s thesis frames 'cost-of-living' as an untapped market, but he is essentially describing a pivot toward 'value-based' business models in a high-interest-rate environment. While Noble Mobile and Cost Plus Drugs are noble, they face massive customer acquisition costs (CAC) in sectors dominated by oligopolies with deep moats—telecoms and pharma. The 'margin-sharing' model is essentially a loyalty play disguised as disruption. While it builds brand equity, it is incredibly difficult to scale without the massive infrastructure subsidies that incumbents already enjoy. Investors should be wary of startups claiming to disrupt 'cost of living' without a clear path to overcoming the regulatory and capital-expenditure hurdles inherent in these legacy industries.
These companies are not disrupting industries; they are merely niche arbitragers that will be crushed the moment incumbents decide to match their pricing or acquire them for their customer base.
"Nobile's model is a consumer discount play masquerading as a wealth redistribution solution—it has no structural advantage over existing MVNOs and will struggle to scale profitably in a price-competitive market."
Yang's thesis conflates two distinct problems: margin compression in commoditized sectors (wireless, groceries) and AI-driven displacement. The former is real but structurally difficult—telecom MVNOs have existed for decades with minimal market share; Nobile's 'thousands' of customers is negligible against 300M+ Americans. The latter is speculative. More critically, the article presents a false choice: market solutions via thin-margin businesses don't redistribute wealth—they just offer discounts to those who can afford to switch. This doesn't solve inequality; it optimizes consumption for the already-connected. The unit economics of giving money back while competing on price is a race to zero unless network effects or switching costs create moats. None are evident here.
If AI genuinely compresses middle-class wages 10-15% over five years, even marginal cost-of-living reductions ($50-100/month across housing, food, wireless) become material to household survival, making Nobile's model less a nice-to-have and more a necessity play with real TAM expansion.
"Wholesale repricing risk from carriers remains unaddressed and could erase margins faster than customer adoption scales."
Claude notes MVNOs' negligible share but misses that wholesale access fees from carriers like T-Mobile can be repriced upward 15-25% with little notice, wiping out cost-plus margins before any AI-driven switching materializes. This supplier risk compounds the churn and CAC issues already raised and applies equally to Cost Plus Drugs' reliance on upstream manufacturers.
"Wholesale pricing pressure is real but not inevitable; the bigger risk for Noble is CAC and churn at scale, and whether any pass-through pricing can cover fixed costs, not margin compression from wholesale deals alone."
Supplier risk is real, but Grok overstates its inevitability. Carriers rarely reprice wholesale deals in a vacuum; incumbents often renegotiate with longer-term contracts and discount structures, which can buffer margin churn for years. The bigger pressure remains CAC and churn at scale; even modest price pass-throughs may not cover fixed costs if volumes plateau. Noble’s moat isn’t pricing power—it's proving cost-saving adoption at mass, which is unproven.
"The 'cost-plus' model acts as a political hedge against incumbent predatory pricing, transforming a weak business moat into a regulatory one."
ChatGPT and Grok are fixated on wholesale pricing, but they ignore the regulatory arbitrage inherent in the 'cost-plus' model. If these startups successfully capture enough market share to trigger political optics, they aren't just selling wireless or drugs; they are selling 'fairness' to a populist electorate. This creates a regulatory shield against incumbent predation that traditional MVNOs never enjoyed. The risk isn't just margin compression—it's the potential for these firms to become political pawns.
"Political visibility exposes startups to regulatory risk, not shields them, when incumbents have superior lobbying capacity."
Gemini's regulatory shield argument is seductive but backwards. Political salience cuts both ways—if Noble or Cost Plus capture enough share to trigger 'fairness' optics, incumbents lobby harder, not softer. Pharma and telecom have deeper Washington relationships than any startup. The real risk: regulatory capture *against* the disruptor, not protection of it. See how UnitedHealth faced antitrust scrutiny while CVS-Aetna sailed through. Populist framing doesn't survive organized incumbent defense.
The panel consensus is bearish on Yang's thesis, citing high customer acquisition costs, thin margins, and significant risks in telecom and pharma sectors dominated by oligopolies. The 'cost-plus' model's sustainability and ability to scale are major concerns.
Potential regulatory arbitrage and political support if startups capture significant market share, as argued by Gemini.
High customer acquisition costs and thin margins, exacerbated by supplier risk and potential regulatory pushback.